Why the study?
Molecular biological approaches have identified genetic variations contributing to cardiac failure, but distinguishing beneficial from maladaptive myocardial hypertrophy remains unclear.
Key points are not available for this paper at this time.
Comparison
Compensatory versus maladaptive myocardial hypertrophy pathways
Design
Review of experimental animal and clinical studies
No takes yet. Share an insight, caveat, or question.
Distinguishes beneficial from maladaptive hypertrophy as potential targets; leaves open clinical translation pending prospective validation.
Daniel J. Lips (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: